Have you been paying attention to shares of ChromaDex (CDXC) ? Shares have been on the move with the stock up 122.5% over the past month. The stock hit a new 52-week high of $7.85 in the previous session. ChromaDex has gained 433.6% since the start of the year compared to the -0.2% move for the Zacks Medical sector and the -8.2% return for the Zacks Medical - Biomedical and Genetics industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't missed ou ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive.Inves ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even though momentum is a popular stock char ...

Shares of ChromaDex (CDXC) have been strong performers lately, with the stock up 72.9% over the past month. The stock hit a new 52-week high of $6.18 in the previous session. ChromaDex has gained 301.4% since the start of the year compared to the 3.1% move for the Zacks Medical sector and the -2.3% return for the Zacks Medical - Biomedical and Genetics industry.What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings consensus est ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate rev ...

业绩总结 - 公司第三季度总净销售额为2560万美元，同比增长31%[9] - Tru Niagen®的净销售额为1810万美元，同比增长4%[9] - Niagen®成分销售额达到670万美元，同比增长368%[9] - 公司实现净收入190万美元，每股收益0.02美元，同比改善280万美元和0.03美元[10] - 调整后的息税折旧摊销前利润（Adjusted EBITDA）为290万美元，较去年同期的50万美元显著改善[10] - 2024年第三季度净销售额为25,580千美元，较2023年第三季度的19,495千美元增长了31.5%[29] - 2024年净销售额预计为83,570千美元，同比增长约15%[40] 用户数据 - 截至2024年10月31日，公司现金余额为3240万美元，无债务[10] - 2024年第三季度现金余额为32,398千美元，较2023年第三季度的26,773千美元增加了5,625千美元[37] - 2024年第三季度的股东权益为34,369千美元，较2023年第四季度的28,456千美元增加了5,913千美元[36] 毛利与费用 - 公司毛利率为63.5%，较去年同期提高210个基点[9] - 2024年第三季度毛利润为16,240千美元，占净销售额的63.5%，较2023年第三季度的61.4%提高了210个基点[29] - 销售和营销费用占净销售额的比例为27.5%，较去年同期改善350个基点[9] - 2024年第三季度销售和市场营销费用为7,044千美元，占净销售额的27.5%，较2023年第三季度的31.0%有所下降[29] - 2024年第三季度总运营费用为14,638千美元，较2023年第三季度的13,116千美元有所增加[29] 未来展望与策略 - 2024年全年净销售增长预期调整为约15%[12] - 2024年将继续专注于品牌建设和新市场的投资[40] - 2024年将增加对新创新的研发投资[40] - 目前有101项关于烟酰胺核糖的临床研究在进行中[47] 研发与创新 - 2023年研发费用为4,958千美元，较2022年4,826千美元有所增加[40] - 包含员工保留税收抵免相关的2,100千美元（无现金流影响）[38]

ChromaDex (CDXC) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 100%. A quarter ago, it was expected that this natural products company would post a loss of $0.03 per share when it actually produced break-even earnings, delivering a surprise of 100%.Over the last four quarters, the compa ...

财务状况 - 公司2021年第四季度营收为1.38亿美元，同比增长18%。[1] - 公司2021年全年营收为5.13亿美元，同比增长22%。[1] - 公司2021年第四季度毛利率为78.5%，同比提高1.5个百分点。[1] - 公司2021年全年毛利率为77.9%，同比提高1.1个百分点。[1] 业务发展 - 公司在2021年第四季度新增了超过1,000家付费客户，总付费客户数达到约15.5万家。[1] - 公司在2021年全年新增了超过4,000家付费客户。[1] - 公司在2021年第四季度的平均每客户年度合同价值(ARPC)为1,020美元，同比增长10%。[1] - 公司在2021年全年的ARPC为1,010美元，同比增长9%。[1] 未来展望 - 公司预计2022年第一季度营收将在1.41亿美元至1.42亿美元之间。[1] - 公司预计2022年全年营收将在5.75亿美元至5.85亿美元之间。[1] - 公司预计2022年第一季度毛利率将在77%至78%之间。[1] - 公司预计2022年全年毛利率将在77%至78%之间。[1]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) | --- | --- | --- | |----------------------------------------------------------------------------------|----------------------------|---------------------------------------------- ...

We expect investors to focus on the sales performance of ChromaDex Corp.'s (CDXC) marketed product, Niagen, and updates on the pipeline when it reports third-quarter 2024 results on Oct. 31, after market close. The Zacks Consensus Estimate for the to-be-reported quarter's revenues is pegged at $23.70 million, while the same for earnings is pinned at 1 cent per share. Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar. Let's see how things might have shaped up for the quarter to be repo ...